Sebclair™ cream is the No. 1 treatment for seborrheic dermatitis in the US, and it is now available in Malaysia. Sebclair™ is indicated to manage and relieve the itching, burning, scaling and pain experienced with SD. It is a non-steroidal, barrier enhancing, mildly keratolytc composition of ingredients formulated to help normalise skin physiology which has been altered by SD and cradle cap in infants. Sebclair™ helps relieve dry waxy skin by maintaining a moist skin environment, which is beneficial to the healing process. Sebclair™ cream can be used to control inflammation and the build-up of scaling on the skin. It is easy-to-use, patients only need to apply three times a day on affected areas and gently massage into the skin. Sebclair™ cream is available on prescription by doctors all over Malaysia.
Sebclair™ cream, (PRONOUNCED: seb-o-REE-ik) dermatitis in America was launched on 17 January 2016 by A.Menarini Singapore Pte Ltd, a subsidiary of the leading bio-pharmaceutical company in Italy at the Hilton Kuala Lumpur. Being the latest addition to Menarini’s range of innovative and clinically-proven dermatitis treatments, Sebclair™ is the first NON-STEROIDAL ANTI-INFLAMMATORY TOPICAL MEDICAL DEVICE CREAM (TMD) INDICATED FOR SEBORRHEIC DERMATITIS (SD) to be introduced in Malaysia.
SD is a common skin condition that affects areas of the body with a particularly high concentration of sebaceous glands. This may include the eyebrows, bridge of the nose, nasolabial folds, ears and chest. It manifests as erythema, which progresses to flakiness and at its most severe, crusting of the skin. SD of the scalp is also particularly common, and in its mildest form may be referred to as dandruff.
Often underdiagnosed, SD does not affect your overall health, but it can be uncomfortable and cause embarrassment. This skin disorder may need many repeated treatments before the symptoms go away. There is no cure for SD, but there is a wide range of products available to treat its signs and symptoms.
SD also often appears as cradle cap in infants. It usually clears by 12 months but can be a persistent problem during this time. The condition is also most common in middle age or older people. It may also be associated with those with a suppressed immune system, HIV and neurological conditions such as Parkinson’s disease.
At present there are various approaches to the management of SD but there is no `gold-standard’ product. Many of the treatments focus on the potential presence of fungi or other organisms on the surface of the skin, and topical corticosteroids are also frequently employed. Although topical corticosteroids are commonly used, they are also disliked, as this group of drugs may have unfavourable side effects, especially when used long-term or on sensitive areas of skin such as the face, hands, or on children. These effects vary from mild and reversible thinning, to irreversible telangiectasiae (fine blood vessels becoming visible at the surface of the skin), striae distensae (marks similar in appearance to `stretch marks’) and Cushing syndrome (a round-shaped face, upper body weight gain, and skin that bruises easily). Steroids’ effectiveness may also become less effective with continued use, which may lead to the escalation to a more potent steroid. There may also be a risk of growth suppression and adrenal suppression in children with the use of topical steroids.
Sebclair™ cream is approved for use in Malaysia as a medical device cream and is indicated for the treatment of SD in both infants and adults. It is a non-steroidal cream that has demonstrated both anti-inflammatory and antifungal properties. Sebclair™ for treatment of SD has comparable efficacy and fewer relapses than a low-potency topical corticosteroid. Sebclair™ has been recommended as a first-line treatment for seborrheic flares and for long-term maintenance in the newly published Asian SD Consensus Guideline Handbook. It has the potential to replace both anti-inflammatory and antifungal treatments in SD patients.
Sebclair™ contains several active ingredients to offer a complete approach to treat SD. Shea butter acts an emollient that helps protect and restore the skin barrier. Propylene glycol and acifructol complex acts as a keratolytic agent to soften and shed the scaly outer layer of the skin. Sebclair™ cream has been shown to work within days in babies diagnosed with cradle cap as presented in real patient case studies by Malaysian paediatricians during the launch.
To address the redness and inflammation, Sebclair™ cream offers an arsenal of anti-inflammatory and anti-itch agents: glycyrrhetinic acid (licorice root extract), bisabolol (chamomile extract) and allantoin. To boost the immunity of the skin cells, Sebclair™ comes with a plethora of antioxidants namely vitamins C and E, vitis vinifera (grapevine) and telmesteine.
As the yeast-like fungi Malassezia sp. are commonly found among SD patients, Sebclair™ also contains piroctone olamine, an antimycotic agent to destroy or prevent the growth of this fungi.
Speaking at the launch was Prof Dr Giuseppe Micali, Head of Dermatology Department and Dermatologist Residency Program Director, University of Catania, Italy, who highlighted the limitations of the current treatment for SD.
“In my experience, when there’s an inflammation, topical anti-fungals are not very effective. So, we need a combination of therapies. For the past years, there’s a need for a new treatment. There needs to be non-prescription agents, such as non-steroidal anti-inflammatory and antifungal that represents a promising approach in the management of some mild to moderate forms of SD, as demonstrated by in vitro and in vivo studies,” he said.
Sebclair™ has no restrictions on patient’s age, duration of use or areas of application. It is well-tolerated to be applied on the face too. Sebclair™ does not contain steroids or immune-suppressing agents. Sebclair™ is a topical medical device cream that is effective as a single therapy (monotherapy) in the treatment of mild to moderate SD. Prof Micali shared that it is possible that the effectiveness of the cream is due to a synergistic effect of piroctone olamine (antimycotic action), propylene glycol (keratolytic action), allantoin and glycyrrhetinic acid (anti-inflammatory action).
For your nearest clinic with Sebclair™ cream, contact Menarini +603 7985 7000.
